Are we ready to translate t-cell transmigration in stroke?

Stroke

Volumn 45, Issue 6, 2014, Pages 1610-1611

  Schäbitz, Wolf Rüdiger ^a   Dirnagl, Ulrich ^b  

^a Department of Neurology EvKB Bethel ^*  (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

inflammation; integrin alpha4; stroke

Indexed keywords

ALPHA4 INTEGRIN; MONOCLONAL ANTIBODY; NATALIZUMAB; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; EDITORIAL; HUMAN; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE MIGRATION; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; T LYMPHOCYTE;

INFLAMMATION; INTEGRIN ALPHA4; STROKE;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BRAIN ISCHEMIA; CELL MOVEMENT; INTEGRIN ALPHA4; MALE; STROKE; T-LYMPHOCYTES;

EID: 84901924257     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.005294     Document Type: Editorial

References (14)

1. Magnus T, Wiendl H, Kleinschnitz C. Immune mechanisms of stroke. Curr Opin Neurol. 2012;25:334-340.
2. Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U. Central nervous system injury-induced immune defciency syndrome. Nat Rev Neurosci. 2005;6:775-786.
3. Liesz A, Zhou W, Mracskó E, Karcher S, Bauer H, Schwarting S, et al. Inhibition of lymphocyte traffcking shields the brain against deleterious neuroinfammation after stroke. Brain. 2011;134(pt 3):704-720.
4. Relton JK, Sloan KE, Frew EM, Whalley ET, Adams SP, Lobb RR. Inhibition of alpha4 integrin protects against transient focal cerebral ischemia in normotensive and hypertensive rats. Stroke. 2001;32:199-205.
5. Becker K, Kindrick D, Relton J, Harlan J, Winn R. Antibody to the alpha4 integrin decreases infarct size in transient focal cerebral ischemia in rats. Stroke. 2001;32:206-211.
6. Effect of natalizmab on infarct volume in acute ischemic stroke (ACTION). ClinicalTrials.gov identifer: NCT01955707. Accessed March 7, 2014.
7. Langhauser F, Kraft P, Göb E, Leinweber J, Schuhmann M, Lorenz K, et al. Blocking alpha4 integrin does not protect from acute ischemic stroke. Stroke. 2014:45:1799-1806.
8. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8:e1000412.
9. Minnerup J, Wersching H, Diederich K, Schilling M, Ringelstein EB, Wellmann J, et al. Methodological quality of preclinical stroke studies is not required for publication in high-impact journals. J Cereb Blood Flow Metab. 2010;30:1619-1624
10. O'Collins. 1, 026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467-477.
11. Dirnagl U, Hakim A, Macleod M, Fisher M, Howells D, Alan SM, et al. A concerted appeal for international cooperation in preclinical stroke research. Stroke. 2013;44:1754-1760.
12. Zechariah A, ElAli A, Hermann DM. Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice. Stroke. 2010;41:1008-1012.
13. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycopro-tein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007;115:2323-2330.
14. Furuya K, Takeda H, Azhar S, McCarron RM, Chen Y, Ruetzler CA, et al. Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study. Stroke. 2001;32:2665-2674.